Navigation Links
Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Date:1/6/2009

n financial requirements and adhere to NASDAQ's corporate governance standards.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These risks and uncertainties include, without limitation, the Company's ability to achieve compliance with the NASDAQ Capital Market's continued listing requirements by February 12, including the market value of listed securities requirement, as well as other risks and uncertainties that could affect the Company's business operations and the development of the Company's products including the Company's need to raise additional capital, risks associated with preclinical and clinical developments in the biopharmaceutical industry in general including, without limitation, the potential failure of a product to prove safe and effective for treatment of a specific condition, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling the product(s). You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Media Contact:
     Dan Eramian
   
'/>"/>
SOURCE  Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 

Related biology technology :

1. Horizon Therapeutics Announces Senior Management Appointments
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
3. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
4. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
5. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
7. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
8. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
9. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
10. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Munich lab demonstrates diesel truck engine with barely measurable emissions 2Munich lab demonstrates diesel truck engine with barely measurable emissions 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 1Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 2Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 3Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 4Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 5Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 6Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 7Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 8Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 9Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 10Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 11Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 12Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 13Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 14Reportlinker Adds Omega Fatty Acids 3A Trends in the Worldwide Food and Beverage Markets 2nd Edition Report 57990 15Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 1Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 2Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 3Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 4Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 5Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 6Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 7Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 8Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 9Reportlinker Adds High Tech Patient Monitoring Systems Markets 28Remote and Wireless Systems Data Processing EMR Data Transfer 29 Report 14210 10SC Johnson a Best Company for Working Moms 57985 1SC Johnson a Best Company for Working Moms 57985 2SC Johnson a Best Company for Working Moms 57985 3